Firas Abu Akar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Firas Abu Akar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anas Salhab
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication - Fahim Kanani
Department of Transplantation Surgery, Rabin Medical Center–Beilinson Hospital, Petah Tikva 4941492, Israel
1 shared publication - Kinda Abu Hashhash
Faculty of Medicine, Al-Quds University, East Jerusalem 20002, Palestine
1 shared publication - Leonardo Chamovitz
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6139001, Israel
1 shared publication - Mohammad Mohtaseb
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6139001, Israel
1 shared publication - Mohammad W. Awlad Mohammad
Faculty of Medicine, Al-Quds University
1 shared publication
Latest Publications
- Open Access
- 17 March 2026
- Published by MDPI AG in Surgical Techniques Development
- Vol. 15 (1) , 12
The Feasibility of Uniportal Video-Assisted Thoracic Surgery in Octogenarians: A Propensity-Matched Comparative Analysis
Objectives: To evaluate the short-term safety (30-day and in-hospital morbidity and mortality) and technical feasibility of uniportal video-assisted thoracic surgery (U-VATS) for anatomical lung resection in octogenarians (≥80 years) compared with younger patients (p = 0.012) and DLCO (68.4 ± 12.1% vs. 78.5 ± 14.3%, p = 0.009), consistent with age-related pulmonary changes. Charlson Comorbidity Index was higher (5.3 ± 1.2 vs. 3.8 ± 1.4, p = 0.001). Surgical parameters were comparable: operative time (143.80 ± 42.3 vs. 136.55 ± 38.7 min, p = 0.524), blood loss (median 80 [IQR 50–120] vs. 95 [IQR 60–130] mL, p = 0.742). Zero conversions occurred. Major complications (Clavien–Dindo ≥ 3) occurred in 10% vs. 0% (absolute risk difference 10%, 95% CI: −3.2% to 23.2%). No 30-day mortality. 90-day mortality: 5% vs. 0% (p = 0.333); one-year: 15% vs. 0% (p = 0.035). Conclusions: U-VATS is technically feasible in carefully selected octogenarians with comparable intraoperative parameters to younger patients. Postoperative recovery differed meaningfully, with higher delirium rates, longer hospitalization, and greater rehabilitation needs. One-year mortality was higher in octogenarians, reflecting competing comorbid risk rather than surgical harm. Residual imbalance in comorbidity burden and pulmonary reserve after matching limits causal inference. These hypothesis-generating findings support U-VATS in selected octogenarians when comprehensive geriatric assessment and structured delirium prevention guide perioperative management; validation in larger multicenter prospective studies is required.
- 17 March 2026
- Published by MDPI AG in Surgical Techniques Development
- Vol. 15 (1) , 12
Open AccessThe Feasibility of Uniportal Video-Assisted Thoracic Surgery in Octogenarians: A Propensity-Matched Comparative Analysis
Objectives: To evaluate the short-term safety (30-day and in-hospital morbidity and mortality) and technical feasibility of uniportal video-assisted thoracic surgery (U-VATS) for anatomical lung resection in octogenarians (≥80 years) compared with younger patients (p = 0.012) and DLCO (68.4 ± 12.1% vs. 78.5 ± 14.3%, p = 0.009), consistent with age-related pulmonary changes. Charlson Comorbidity Index was higher (5.3 ± 1.2 vs. 3.8 ± 1.4, p = 0.001). Surgical parameters were comparable: operative time (143.80 ± 42.3 vs. 136.55 ± 38.7 min, p = 0.524), blood loss (median 80 [IQR 50–120] vs. 95 [IQR 60–130] mL, p = 0.742). Zero conversions occurred. Major complications (Clavien–Dindo ≥ 3) occurred in 10% vs. 0% (absolute risk difference 10%, 95% CI: −3.2% to 23.2%). No 30-day mortality. 90-day mortality: 5% vs. 0% (p = 0.333); one-year: 15% vs. 0% (p = 0.035). Conclusions: U-VATS is technically feasible in carefully selected octogenarians with comparable intraoperative parameters to younger patients. Postoperative recovery differed meaningfully, with higher delirium rates, longer hospitalization, and greater rehabilitation needs. One-year mortality was higher in octogenarians, reflecting competing comorbid risk rather than surgical harm. Residual imbalance in comorbidity burden and pulmonary reserve after matching limits causal inference. These hypothesis-generating findings support U-VATS in selected octogenarians when comprehensive geriatric assessment and structured delirium prevention guide perioperative management; validation in larger multicenter prospective studies is required.
- Open Access
Disparities in Thoracic Oncology Patients
Background/Objectives: Lung cancer is one of the major causes of mortality worldwide despite breakthroughs in screening, diagnosis, and treatment. These advances have not been evenly spread, and discrepancies between populations remain concerning. This article examines lung cancer discrepancies in epidemiology, risk factors, screening, diagnosis, treatment access and quality, and survival outcomes, and identifies the main causes. Methods: An extensive narrative evaluation of peer-reviewed literature, national cancer surveillance reports, and large population-based research was searched. The evidence on lung cancer disparities by race, ethnicity, socioeconomic status, sex, geography, and healthcare access was synthesized. Disparities in prevention, early identification, treatment, and outcomes were organized into this paper. Results: Lung cancer incidence, stage, treatment, and survival showed persistent differences. Racial and ethnic minority groups, people on low-incomes, uninsured people, and rural or resource-limited people had higher disease burden and worse outcomes. Access to low-dose computed tomography screening, rapid diagnostic follow-up, surgical resection, molecular testing, targeted medicines, immunotherapy, palliative care, and clinical trials was unequal. When guidelines are followed, survival outcomes are similar across races and ethnicities. Conclusions: Lung cancer disparities are mostly caused by structural, social, and healthcare system factors, not biology. Coordinated measures to provide equitable screening, prompt and high-quality treatment, research inclusion, and culturally sensitive and policy-driven actions are needed to enhance lung cancer outcomes.
Open AccessDisparities in Thoracic Oncology Patients
Background/Objectives: Lung cancer is one of the major causes of mortality worldwide despite breakthroughs in screening, diagnosis, and treatment. These advances have not been evenly spread, and discrepancies between populations remain concerning. This article examines lung cancer discrepancies in epidemiology, risk factors, screening, diagnosis, treatment access and quality, and survival outcomes, and identifies the main causes. Methods: An extensive narrative evaluation of peer-reviewed literature, national cancer surveillance reports, and large population-based research was searched. The evidence on lung cancer disparities by race, ethnicity, socioeconomic status, sex, geography, and healthcare access was synthesized. Disparities in prevention, early identification, treatment, and outcomes were organized into this paper. Results: Lung cancer incidence, stage, treatment, and survival showed persistent differences. Racial and ethnic minority groups, people on low-incomes, uninsured people, and rural or resource-limited people had higher disease burden and worse outcomes. Access to low-dose computed tomography screening, rapid diagnostic follow-up, surgical resection, molecular testing, targeted medicines, immunotherapy, palliative care, and clinical trials was unequal. When guidelines are followed, survival outcomes are similar across races and ethnicities. Conclusions: Lung cancer disparities are mostly caused by structural, social, and healthcare system factors, not biology. Coordinated measures to provide equitable screening, prompt and high-quality treatment, research inclusion, and culturally sensitive and policy-driven actions are needed to enhance lung cancer outcomes.